Astech Projects Limited

During 2025, the Company continued to invest in its people, products and operational capabilities to strengthen its market position and support future growth. A key focus during the period has been the continued development and commercialisation of the Company’s new product range, designed to expand its ability to deliver advanced automation solutions to customers within the pharmaceutical, petrochemical and laboratory sectors. This investment programme has impacted the financial performance of the Company in the short term; however, these investments are intended to support future revenue growth and strengthen the Company’s competitive position within its specialist markets. The Company has continued to receive both strategic and financial support from its parent company, Schauenburg International. In January 2025, £827,253 of shareholder funding was converted into equity and a further £700,000 was invested as capital during the year, further strengthening the Company’s balance sheet and demonstrating the continued support of the shareholder. Looking ahead, the directors remain focused on securing new customer orders, progressing the commercial rollout of the Company’s new products, and continuing to develop the Company’s capabilities in automation, drug delivery and laboratory systems. The directors believe the Company remains well positioned to benefit from future opportunities within its core markets.